Meng Zhao

Dr. Meng Zhao

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2025 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
JWJian Wang
Jian Wang
MZMeng Zhao
Meng Zhao
JZJian Zhang Zhang
Jian Zhang Zhang
Xiaoyan ZhangXiaoyan Zhang
Xiaoyan Zhang
HZHongming Zhu
Hongming Zhu
SZSong Zhang
Song Zhang
Doxorubicin (DOX), a member of the anthracycline family, is widely recognized as an effective chemotherapeutic agent for cancer treatment. However, its cli

17 October 2025 in ACS Omega
Verified
Journal Article
Open access
SLShujia Liu
Shujia Liu
HZHaojin Zhou
Haojin Zhou
WBWeihua Bian
Weihua Bian
KHKanghui Huan
Kanghui Huan
MZMeng Zhao
Meng Zhao
JWJiaqi Wang
Jiaqi Wang
Cardiovascular disease remains a leading cause of global mortality, underscoring the urgent need for novel therapeutic strategies. This study focuses on the pleckstrin homology-like domain family A member 1-encoded protein (PEP), a regulator of cardiomyocyte apoptosis and a promising yet underexplored therapeutic target. Leveraging an integrated computational approach, we combined AlphaFold3-based structure prediction with extensive molecular dynamics simulations to characterize PEP's dynamic architecture and identify high-affinity dipeptide inhibitors. Our results reveal that PEP possesses significant intrinsic disorder, with molecular dynamics simulations refining its conformation and highlighting force field-dependent behaviors, particularly the superior performance of CHARMM-class force fields in preserving functional secondary structures. High-throughput screening of phenylalanine-based dipeptides identified FF as the strongest binder, exhibiting a unique aggregation-mediated binding mechanism that engages both primary and secondary sites on PEP through multivalent interactions. Concentration-dependent simulations further confirmed the robustness of FF binding and revealed residue-specific interaction hotspots. Notably, we demonstrate that low-confidence regions in AF3 predictions (pLDDT <50) frequently participate in functional binding, challenging the conventional lock-and-key paradigm. These findings not only establish PEP as a tractable drug target but also provide a novel framework for designing aggregation-prone peptide therapeutics against cardiovascular diseases.

5 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SLShujia Liu
Shujia Liu
HZHaojin Zhou
Haojin Zhou
MZMeng Zhao
Meng Zhao
JWJiaqi Wang
Jiaqi Wang
The PHLDA1-encoded protein (PEP) is a pivotal regulator of cardiomyocyte apoptosis and a promising therapeutic target for cardiovascular diseases. Leveraging in silico approaches, we characterized PEP's structure using AlphaFold3 (AF3) and refined it via molecular dynamics (MD) simulations with various force fields. Kinetic and thermodynamics analysis further confirmed revealed that the Amber99 force field induced the most significant structural change, with the most significant decrease in radius of gyration and lowest potential energy. High-throughput screening of 20 phenylalanine-based dipeptides (FA-FY) revealed sequence-dependent binding to PEP, with FF, FH, FP, and FY exhibiting the maximum count of binders (11, 7, 6, and 6, respectively). Key residues (e.g., L55, C60, E142, E89) formed a continuous binding groove, while FF dipeptides demonstrated cooperative aggregation-enhanced binding. Notably, low-pLDDT regions (< 50) frequently participated in ligand interactions, challenging the rigid "lock-and-key" paradigm and underscoring the role of intrinsic disorder in binding. this work establishes PEP as a tractable target for dipeptide inhibitors and provides a computational framework for designing peptide-based therapeutics against cardiac injury.